TCGA-CV-7245-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.400
- TGF_BETA_SIGNALING+0.400
- MYC_TARGETS_V2+0.390
- HEDGEHOG_SIGNALING+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- E2F_TARGETS+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- MYC_TARGETS_V1+0.300
- MTORC1_SIGNALING+0.290
- UV_RESPONSE_DN+0.290
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.410
- INTERFERON_GAMMA_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.280
- COMPLEMENT-0.180
- BILE_ACID_METABOLISM-0.140
- IL6_JAK_STAT3_SIGNALING-0.140
- KRAS_SIGNALING_UP-0.140
- OXIDATIVE_PHOSPHORYLATION-0.130
- APICAL_SURFACE-0.100
- ADIPOGENESIS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598197 | fetal | fetal | 0.817 |
| 2 | TCGA-56-7582-01A-11R-2045-07 | — | cohortSQ2 | 0.815 |
| 3 | MNG1297 | — | — | 0.786 |
| 4 | SRR1313118 | — | B | 0.781 |
| 5 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.778 |
| 6 | MDT-AP-0007 | Med | Medulloblastoma | 0.777 |
| 7 | ERR2598184 | fetal | fetal | 0.768 |
| 8 | TCGA-E2-A1LL-01A-11R-A144-07 | — | C | 0.764 |
| 9 | C3N-03662 | — | cohortSQ2 | 0.762 |
| 10 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.240 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |